Skip to content

Evaluation of the Effectiveness of Calcium Dobesilate in Improving Symptoms of Patients with Venous Reflux After Great Saphenous Vein Stripping Surgery

A clinical trial studying the effectiveness of calcium dobesilate in reducing symptoms in patients with SFJ and GSV reflux after great saphenous vein stripping surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251220068389N1
Enrollment
42
Registered
2026-04-04
Start date
2026-06-13
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic venous insufficiency with saphenofemoral junction and great saphenous vein reflux. Venous insufficiency (chronic) (peripheral)

Interventions

Intervention 1: Intervention group: Calcium dobesilate 500 mg capsules twice daily (total daily dose 1000 mg) for 4 weeks plus standard postoperative care including compression therapy, wound care, an

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients (18 years of age or older) with SFJ and GSV reflux Written Patients who have indication for great saphenous vein stripping surgery informed consent and Ability to comply with study procedures

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Severe cardiovascular, hepatic or renal disease Active malignancy Previous adverse reactions to calcium dobesilate Concomitant use of anticoagulant or antiplatelet drugs (except aspirin = 100 mg) Active venous ulcer (C6) Planned additional vascular procedures during the study period

Design outcomes

Primary

MeasureTime frame
Change in the total score of the Aberdeen Varicose Vein Questionnaire from baseline to 4 weeks after great saphenous vein stripping surgery. Timepoint: Baseline before surgery or within 72 hours after surgery, week 2, and week 4 after surgery. Method of measurement: Self-administered validated Persian version of the Aberdeen Varicose Vein Questionnaire completed by the patient at each visit.

Secondary

MeasureTime frame
Change in Visual Analogue Scale pain score from baseline to 4 weeks after great saphenous vein stripping surgery. Timepoint: Baseline before surgery or within 72 hours after surgery, week 2, and week 4 after surgery. Method of measurement: Patient reported Visual Analogue Scale zero to ten centimeter scale for leg pain completed at each visit.;Change in lower limb circumference at ankle and calf levels from baseline to 4 weeks after great saphenous vein stripping surgery. Timepoint: (Baseline + ???? ? + ???? ?). Method of measurement: Standardized tape measure circumference at the malleolar level for ankle and at the widest point of the calf.;Change in Chronic Venous Insufficiency Quality of Life Questionnaire score from baseline to 4 weeks after great saphenous vein stripping surgery. Timepoint: (Baseline + ???? ? + ???? ?). Method of measurement: Self-administered validated thirty-item Chronic Venous Insufficiency Quality of Life Questionnaire completed by the patient at each visit.;Patient Global Impression of Change score at 4 weeks after great saphenous vein stripping surgery. Timepoint: Week 4 after surgery. Method of measurement: Seven-point Likert scale patient-reported global impression of change completed at week 4.;Time in days to return to normal daily activities from the day of great saphenous vein stripping surgery. Timepoint: Assessed daily up to 4 weeks after surgery. Method of measurement: Patient self-report of the exact day when usual daily activities were resumed.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArefeh Ghanbarzadeh Hesari

Tehran University of Medical Sciences

hadighi.md@gmail.com+98 21 8823 1389

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026